Holding(s) in Company

RNS Number : 8694J

OptiBiotix Health PLC

14 September 2016

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Holding in Company

The Company was informed on 13 September 2016 that Seneca Partners Limited no longer has a disclosable interest in the Company.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

OptiBiotix Health plc	www.optibiotix.com
Stephen O'Hara, Chief Executive	Contact via Walbrook below
Cairn Financial Advisers LLP	Tel: [phone]
Liam Murray
Hybridan LLP (Joint Broker)	Tel: [phone]
Claire Louise Noyce
Peterhouse Corporate Finance Ltd (Joint Broker)	Tel: [phone]
Lucy Williams / Duncan Vasey
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Anna Dunphy	Mob: [phone]

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

END

 

 

HOLGGUMWBUPQGAC